系统综述与荟萃分析:硫嘌呤可降低炎症性肠病患者结直肠肿瘤风险
该系统综述与荟萃分析纳入24项观察性研究、共76999名参与者,评估硫嘌呤治疗对炎症性肠病(IBD)患者结直肠肿瘤风险的影响。结果显示硫嘌呤使用与IBD患者结直肠肿瘤风险降低相关(OR=0.63,95%CI 0.46-0.86),该效应在溃疡性结肠炎(UC)患者中显著(OR=0.67,95%CI 0.45-0.98),在克罗恩病(CD)患者中不显著(OR=1.06,95%CI 0.54-2.09)。
要点
- 硫嘌呤使用与IBD患者结直肠肿瘤风险降低相关(OR=0.63,95%CI 0.46-0.86)。
- 硫嘌呤与UC患者结直肠肿瘤风险降低显著相关(OR=0.67,95%CI 0.45-0.98)。
- 硫嘌呤与CD患者结直肠肿瘤风险无显著相关(OR=1.06,95%CI 0.54-2.09)。
核心结论
- 该荟萃分析显示硫嘌呤对IBD患者结直肠肿瘤具有抗肿瘤效应,尤其在UC患者中。
研究设计与样本
- 研究为纳入24项观察性研究、共76999名参与者的荟萃分析,采用随机效应模型计算合并OR及95%CI。
主要发现
- 总体合并估计显示硫嘌呤使用对IBD患者结直肠肿瘤具有保护效应(OR=0.63,95%CI 0.46-0.86)。
- 硫嘌呤暴露显著降低结直肠癌风险(OR=0.65,95%CI 0.45-0.96)和进展期结直肠肿瘤(结直肠癌和/或高级别异型增生)风险(OR=0.62,95%CI 0.44-0.89)。
- 硫嘌呤暴露未降低单纯异型增生风险(OR=0.90,95%CI 0.37-2.21)。
- 基于临床的研究(OR=0.59,95%CI 0.42-0.82)和病例对照研究(OR=0.40,95%CI 0.26-0.62)中硫嘌呤保护效应明显,但基于人群的研究(OR=0.95,95%CI 0.55-1.62)和队列研究(OR=0.98,95%CI 0.81-1.18)中未见保护效应。
- 在欧洲开展的研究(OR=0.48,95%CI 0.31-0.77)显示硫嘌呤保护效应,而在北美开展的研究(OR=0.91,95%CI 0.67-1.24)未显示保护效应。
关键数值与推荐
- 硫嘌呤使用与IBD患者结直肠肿瘤风险降低相关(OR=0.63,95%CI 0.46-0.86)。
- 硫嘌呤使用与UC患者结直肠肿瘤风险降低显著相关(OR=0.67,95%CI 0.45-0.98),与CD患者无显著相关(OR=1.06,95%CI 0.54-2.09)。
- 硫嘌呤暴露显著降低结直肠癌风险(OR=0.65,95%CI 0.45-0.96)和进展期结直肠肿瘤风险(OR=0.62,95%CI 0.44-0.89),未显著降低单纯异型增生风险(OR=0.90,95%CI 0.37-2.21)。
临床怎么用
- 作者认为该荟萃分析显示硫嘌呤对IBD患者结直肠肿瘤具有抗肿瘤效应,尤其在UC患者中。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with inflammatory bowel disease (IBD) have a high risk of developing colorectal neoplasia. AIM: To investigate whether thiopurines can decrease the risk of developing colorectal neoplasia in patients with ulcerative colitis (UC) or Crohn's disease (CD). METHODS: We conducted a meta-analysis of 24 observational studies involving 76,999 participants to evaluate the risks of developing colorectal neoplasia in IBD patients receiving thiopurine treatment. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the risks of colorectal neoplasia were calculated using a random-effects model. RESULTS: The overall pooled estimate revealed a protective effect of thiopurine use on colorectal neoplasia in patients with IBD (OR = 0.63, 95% CI 0.46-0.86). The effect was significant in UC patients (OR = 0.67, 95% CI 0.45-0.98), but was not significant in CD patients (OR = 1.06, 95% CI 0.54-2.09). Thiopurines exposure significantly decreased the risk of colorectal cancer (CRC) (OR = 0.65, 95% CI 0.45-0.96) and advanced colorectal neoplasia (CRC and/or high-grade dysplasia) (OR = 0.62, 95% CI 0.44-0.89), but did not decrease the risk of dysplasia alone (OR = 0.90, 95% CI 0.37-2.21). Tendencies towards the protective effect of thiopurines were distinct in clinic-based studies (OR = 0.59, 95% CI 0.42-0.82) and case-control studies (OR = 0.40, 95% CI 0.26-0.62), but not in population-based studies (OR = 0.95, 95% CI 0.55-1.62) and cohort studies (OR = 0.98, 95% CI 0.81-1.18). Interestingly, studies conducted in Europe (OR = 0.48, 95% CI 0.31-0.77), rather than in North America (OR = 0.91, 95% CI 0.67-1.24), showed the protective effect of thiopurines. CONCLUSIONS: This meta-analysis revealed an antineoplastic effect of thiopurines on colorectal neoplasia in patients with IBD, particularly amongst patients with UC.
引用
- Lu MJ, Qiu XY, Mao XQ, et al. Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017. PMID: 29205426. doi:10.1111/apt.14436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。